Carrie Clark
Director of Genspect UK
Carrie Clark, Director of Genspect UK, brings forensic precision to conversations that require it. In her Beyond Gender appearance, she joins Stella O'Malley and Mia Hughes to take apart an NHS puberty blocker trial piece by piece — and makes the case that institutional amnesia, not new evidence, is driving it.
Carrie Clark is Director of Genspect UK, the British arm of an international alliance of professionals, parents, and detransitioners raising sustained concerns about the medical pathway for gender-distressed youth. Her work sits at the intersection of policy scrutiny and clinical evidence — territory that rarely gets the technically literate attention it demands.
In her Beyond Gender appearance, The UK is Restarting a Puberty Blocker Trial Despite 25 Years of Evidence, Clark does something the news cycle rarely manages: she slows down. Alongside hosts Stella O'Malley and Mia Hughes, she unpacks a proposed £10 million NHS puberty blocker trial not as a headline but as a policy object — one with a design, a funding source, and a set of assumptions that can be tested against existing evidence. Her argument is that the trial reflects selective science, activist framing, and an institutional unwillingness to fully reckon with what the Cass Review established.
What makes Clark effective in conversation is the combination of detailed knowledge and composure. She doesn't trade in alarm — she trades in specifics. The episode becomes a tutorial in how to read a clinical trial proposal critically, why methodological choices matter, and what it means for a health system to restart a programme its own review had called into question.
For listeners who followed the Cass Review but aren't sure what came next, this episode maps the terrain. Clark is the guide you want: precise, well-sourced, and clear about what the evidence can and cannot bear.
